Clinical trial
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With…
NCT00247663 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00247663 |
|---|---|
| Title | Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer |
| Official title | Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | Chugai Pharmaceutical Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Postmenopausal Women With Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 17 |
| Start date | Dec 1, 1999 |
| Primary completion | Dec 1, 2005 |
| First posted | Nov 2, 2005 |
| Last update posted | Apr 19, 2012 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: